Smarter Insights, Better Outcomes: Using SNP Testing to Accelerate Personalized Patient Care
September 11, 2026
Overview
Your genes reveal where you might be vulnerable, but true clinical impact comes from understanding how that risk translates into action. With the new DNA Signature profiles, Mosaic Diagnostics bridges the gap between raw genomic data and personalized patient care, moving beyond isolated genetic variants to evaluate their collective influence across multiple pathways. By combining advanced genomic science with polygenic risk scoring within a real-world clinical context, this approach transforms complex data into clear, evidence-based recommendations for nutrition, supplementation, lifestyle changes, and targeted follow-up testing.
Join this live event to learn how DNA Signature empowers practitioners in delivering more precise, individualized care while reducing trial and error in treatment planning. Through actionable reports and tailored recommendations, providers can better support patient outcomes and accelerate progress toward optimal health.
Objectives
Learning Objectives
By the end of this webinar, participants will be able to:
- Decode the Science: Understand the role of single nucleotide polymorphism (SNPs) and polygenic risk scoring in DNA Signature test reports to evaluate complex health risks within a practical clinical framework.
- Design Targeted Interventions: Translate complex genomic findings into prioritized, evidence-based recommendations for nutrition, supplementation, lifestyle changes, and follow-up testing.
- Streamline Clinical Decision-Making: Integrate genomic insights into personalized care plans to eliminate guesswork, speed up targeted treatment, and boost practice efficiency.
- Drive Patient Outcomes: Utilize evidence-based genomic data to improve patient communication, foster long-term compliance, and accelerate health goals.
About the Author
Scott Mattivi, CEO, Mosaic Diagnostics
Scott Mattivi, CEO of Mosaic Diagnostics, is a visionary leader in the diagnostic laboratory space with nearly 40 years of experience spanning clinical, biopharma, and laboratory operations. Before joining MosaicDX, Scott held executive roles overseeing clinical labs and biopharma/clinical trial services. He most recently served as Chief Operating Officer at Pathology Watch and spent over a decade in progressive leadership positions at Eurofins Viracor BioPharma Services, including President, Vice-President of Operations, and General Manager. He began his career in laboratory management at Quest Diagnostics, where he spent more than 22 years driving growth across various roles.
Originally from Pittsburg, Kansas, Scott holds a degree in Biology from Pittsburg State University, and a Medical Technology degree from the University of Kansas. When not at Mosaic’s headquarters in Kansas, Scott resides in Colorado Springs. He is a devoted husband, father of two grown children, and proud grandfather. Scott’s passions include his faith, his family, the dedicated teams he leads, and the mission of supporting the practitioners who work tirelessly to improve the lives of patients navigating complex, chronic disease.
A Clearer Path to Clinical Insight: Inside the Enhanced Organic Acids Test (OAT) Report
At Mosaic Diagnostics, our goal has always been to make complex biochemistry clinically actionable.
How Mosaic Diagnostics’ Organic Acids Test (OAT) Uncovered the Source Preventing 6-year-old Erin Relax and Fall Asleep
Organic acids are acidic byproducts of cellular metabolism that are produced by living organisms—including humans, bacteria, and fungi—and are typically excreted in urine.
Stay Informed, Stay Ahead
Join the MosaicDX community and elevate your testing knowledge.